ECSP23073082A - Nuevos moduladores alostéricos negativos ciclopenta[c]pirrol de NR2B - Google Patents

Nuevos moduladores alostéricos negativos ciclopenta[c]pirrol de NR2B

Info

Publication number
ECSP23073082A
ECSP23073082A ECSENADI202373082A ECDI202373082A ECSP23073082A EC SP23073082 A ECSP23073082 A EC SP23073082A EC SENADI202373082 A ECSENADI202373082 A EC SENADI202373082A EC DI202373082 A ECDI202373082 A EC DI202373082A EC SP23073082 A ECSP23073082 A EC SP23073082A
Authority
EC
Ecuador
Prior art keywords
nr2b
allosteric modulators
negative allosteric
pyrrole
cyclopenta
Prior art date
Application number
ECSENADI202373082A
Other languages
English (en)
Inventor
Yue Pan
Fan Yang
Keith Jendza
Mark Patrick Healy
Kevin Matthew Gardinier
Kate Yaping Wang
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of ECSP23073082A publication Critical patent/ECSP23073082A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente divulgación proporciona un compuesto de la fórmula (I), o una sal farmacéuticamente aceptable del mismo, un método para fabricar los compuestos de la divulgación y sus usos terapéuticos. La presente divulgación proporciona además una combinación de agentes farmacológicamente activos y una composición farmacéutica.
ECSENADI202373082A 2021-03-26 2023-09-26 Nuevos moduladores alostéricos negativos ciclopenta[c]pirrol de NR2B ECSP23073082A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202163166516P 2021-03-26 2021-03-26

Publications (1)

Publication Number Publication Date
ECSP23073082A true ECSP23073082A (es) 2023-10-31

Family

ID=83396075

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202373082A ECSP23073082A (es) 2021-03-26 2023-09-26 Nuevos moduladores alostéricos negativos ciclopenta[c]pirrol de NR2B

Country Status (16)

Country Link
EP (1) EP4313041A1 (es)
JP (1) JP2024509325A (es)
KR (1) KR20230160906A (es)
CN (1) CN117157072A (es)
AR (1) AR125594A1 (es)
AU (1) AU2022244367A1 (es)
BR (1) BR112023018766A2 (es)
CA (1) CA3212203A1 (es)
CO (1) CO2023012711A2 (es)
CR (1) CR20230458A (es)
DO (1) DOP2023000205A (es)
EC (1) ECSP23073082A (es)
IL (1) IL305601A (es)
TW (1) TW202304885A (es)
UY (1) UY39688A (es)
WO (1) WO2022204336A1 (es)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2879126A1 (en) * 2012-07-19 2014-01-23 Janssen Pharmaceutica Nv Octahydro-cyclopentapyrrolyl antagonists of ccr2
JO3579B1 (ar) * 2014-09-26 2020-07-05 Luc Therapeutics Inc مُعدِلات تفاغرية سالبة لمستقبل nr2b من المركب n-ألكيل أريل-5-أوكسي أريل-ثامن هيدرو-خماسي الحلقة [c] بيرول
CN107849009B (zh) * 2015-10-13 2021-03-02 四川海思科制药有限公司 一种八氢环戊二烯并[c]吡咯衍生物及其制备方法和在医药上的用途

Also Published As

Publication number Publication date
CA3212203A1 (en) 2022-09-29
DOP2023000205A (es) 2023-11-15
UY39688A (es) 2022-10-31
EP4313041A1 (en) 2024-02-07
WO2022204336A1 (en) 2022-09-29
AU2022244367A1 (en) 2023-09-07
CO2023012711A2 (es) 2023-10-19
CR20230458A (es) 2023-10-27
IL305601A (en) 2023-11-01
BR112023018766A2 (pt) 2023-10-24
AR125594A1 (es) 2023-08-02
CN117157072A (zh) 2023-12-01
TW202304885A (zh) 2023-02-01
JP2024509325A (ja) 2024-02-29
KR20230160906A (ko) 2023-11-24

Similar Documents

Publication Publication Date Title
DOP2022000124A (es) Derivados de pirazolilo útiles como agentes anticancerígenos
DOP2022000183A (es) Derivados de biarilo como inhibidores de la interacción proteína-proteína de yap/taz-tead
ECSP11011561A (es) Derivados aminobutíricos sustituidos como inhibidores de neprilisina
ECSP22052564A (es) Tetrahidrofuranos sustituidos como moduladores de canales de sodio
CO6470847A2 (es) Derivados amino-propiónicos sustituidos como inhibidores de neprilisina
UY33075A (es) Derivados de ciclohexano y usos de los mismos
CO2019002618A2 (es) Compuestos de aza–indazol para usar en lesiones de tendones y/o ligamentos
CO2019003894A2 (es) Derivados de naftiridinona y su uso en el tratamiento de la arritmia
CY1124708T1 (el) Φαρμακολογικως δραστικα αλικυκλικα υποκατεστημενα παραγωγα πυραζολο[1,5-a] πυριμιδινης
AR127470A1 (es) Inhibidores de lrrk2
ECSP19084722A (es) Compuestos bicíclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias
ECSP23017158A (es) Derivados de espiropiperidinilo sustituidos con heteroarilo y usos farmacéuticos de los mismos
DOP2020000088A (es) Derivados de piridinona y su uso como inhibidores selectivos de alk–2.
ECSP23073082A (es) Nuevos moduladores alostéricos negativos ciclopenta[c]pirrol de NR2B
UY39722A (es) Nuevos derivados de heteroaril aminopropanol
ECSP22030740A (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
CL2022002490A1 (es) Derivados de biarilo como inhibidores de la interacción proteína-proteína de yap/taz-tead
AR117298A1 (es) Aglutinante de péptido
EA201992577A1 (ru) 5,6-конденсированные бициклические соединения и композиции для лечения паразитарных заболеваний